Survivin expression in normal human bronchial epithelial cells: An early and critical step in tumorigenesis induced by tobacco exposure

Carcinogenesis

Volumn 29, Issue 8, 2008, Pages 1614-1622

  Jin, Quanri ^a   Menter, David G ^a   Mao, Li ^a   Hong, Waun Ki ^a   Lee, Ho Young ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; NICOTINE; SMALL INTERFERING RNA; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHUS MUCOSA; CANCER INHIBITION; CELL IMMORTALIZATION; CELL STIMULATION; CELL SURVIVAL; CIGARETTE SMOKING; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CARCINOGENESIS; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TOBACCO;

APOPTOSIS; BRONCHI; BRONCHIAL NEOPLASMS; CELL CYCLE; CELL LINE; CELL SURVIVAL; DNA, NEOPLASM; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; RNA, SMALL INTERFERING; TOBACCO;

EID: 49649102136     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm234     Document Type: Article

References (48)

1. Parkin,D.M. (2001) Global cancer statistics in the year 2000. Lancet Oncol., 2, 533-543.
2. Hagiwara,N. et al. (2006) Quantitative detection of p53 mutations in plasma DNA from tobacco smokers. Cancer Res., 66, 8309-8317.
3. Tam,I.Y. et al. (2006) Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin. Cancer Res., 12, 1647-1653.
4. Lowe,S.W. et al. (2000) Apoptosis in cancer. Carcinogenesis, 21, 485-495.
5. West,K.A. et al. (2003) Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J. Clin. Invest., 111, 81-90.
6. Lee,H.Y. et al. (2005) Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J. Natl Cancer Inst., 97, 1695-1699.
7. Dasgupta,P. et al. (2006) Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc. Natl Acad. Sci. USA, 103, 6332-6337.
8. Tamm,I. et al. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res., 58, 5315-5320.
9. Takahashi,R. et al. (1998) A single BIR domain of XIAP sufficient for inhibiting caspases. J. Biol. Chem., 273, 7787-7790.
10. Adida,C. et al. (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Pathol., 152, 43-49.
11. Monzo,M. et al. (1999) A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol., 17, 2100-2104.
12. Dan,H.C. et al. (2004) Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene, 23, 706-715.
13. Chun,K.H. et al. (2003) Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J. Natl Cancer Inst., 95, 291-302.
14. Tsao,A.S. et al. (2003) Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: Implications for lung cancer prevention studies. Cancer Epidemiol. Biomarkers Prev., 12, 660-664.
15. Klein-Szanto,A.J. et al. (1992) A tobacco-specific N-nitrosamine or cigarette smoke condensate causes neoplastic transformation of xenotransplanted human bronchial epithelial cells. Proc. Natl Acad. Sci. USA, 89, 6693-6697.
16. Zhang,H. et al. (2007) PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Invest., 117, 730-738.
17. Han,J.Y. et al. (2005) Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J. Natl Cancer Inst., 97, 1272-1286.
18. Morgillo,F. et al. (2006) Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res., 66, 10100-10111.
19. Lee,H.Y. et al. (2004) Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J. Natl Cancer Inst., 96, 1536-1548.
20. Song,Z. et al. (2003) Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J. Biol. Chem., 278, 23130-23140.
21. Jiang,Y. et al. (2004) Aberrant regulation of survivin by the RB/ E2F family of proteins. J. Biol. Chem., 279, 40511-40520.
22. Hoffman,W.H. et al. (2002) Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem., 277, 3247-3257.
23. Jin,Q. et al. (2007) Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguclin. Cancer Res., 67, 11630-11639.
24. Knauer,S.K. et al. (2007) Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J., 21, 207-216.
25. Inoki,K. et al. (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol., 4, 648-657.
26. Hanahan,D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
27. Lee,J.J. et al. (2001) Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J. Natl Cancer Inst., 93, 1081-1088.
28. Tamm,I. et al. (2004) High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin. Cancer Res., 10, 3737-3744.
29. Mesri,M. et al. (2001) Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest., 108, 981-990.
30. Lu,B. et al. (2004) Nuclear survivin as a biomarker for non-small-cell lung cancer. Br. J. Cancer, 91, 537-540.
31. Chiodino,C. et al. (1999) Communication: Expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J. Invest. Dermatol., 113, 415-418.
32. Konno,R. et al. (2000) Expression of survivin and Bcl-2 in the normal human endometrium. Mol. Hum. Reprod., 6, 529-534.
33. O'Connor,D.S. et al. (2000) Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl Acad. Sci. USA, 97, 13103-13107.
34. Du,C. et al. (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell, 102, 33-42.
35. Mao,L. et al. (1997) Clonal genetic alterations in the lungs of current and former smokers. J. Natl Cancer Inst., 89, 857-862.
36. Camps,C. et al. (2005) Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? Lung Cancer, 50, 339-346.
37. Toyooka,S. et al. (2006) Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res., 66, 1371-1375.
38. Kraunz,K.S. et al. (2006) Homozygous deletion of p16INK4a and tobacco carcinogen exposure in nonsmall cell lung cancer. Int. J. Cancer, 118, 1364-1369.
39. Peng,X.H. et al. (2006) Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J. Biol. Chem., 281, 25903-25914.
40. Alberg,A.J. et al. (2005) Epidemiology of lung cancer: Looking to the future. J. Clin. Oncol., 23, 3175-3185.
41. Hallstrom,T.C. et al. (2003) Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc. Natl Acad. Sci. USA, 100, 10848-10853.
42. Mitsiades,C.S. et al. (2002) Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications. Oncogene, 21, 5673-5683.
43. Yang,D. et al. (2004) Cell division and cell survival in the absence of survivin. Proc. Natl Acad. Sci. USA, 101, 15100-15105.
44. Cheng,Y.W. et al. (2001) The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res., 61, 2799-2803.
45. Sasaki,H. et al. (2007) Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung. Lung Cancer, 55, 129-130.
46. Borbely,A.A. et al. (2006) Effects of human papillomavirus type 16 onco-proteins on survivin gene expression. J. Gen. Virol., 87 287-294.
47. Wang,Q. et al. (2005) EGFR enhances survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway. Exp. Mol. Pathol., 79, 100-107.
48. Hofmann,H.S. et al. (2002) Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. J. Cancer Res. Clin. Oncol., 128, 554-560.